Excess Death Trends

Neale Hanvey Excerpts

Tuesday 16th January 2024 Westminster Hall

[Neale Hanvey (Kirkcaldy and Cowdenbeath) (Alba)]

Time is tight, so I will cut to the chase. I pay tribute to the hon. Member for North West Leicestershire (Andrew Bridgen) for his courage and determination on this important matter. I also challenge the right hon. Member for Knowsley (Sir George Howarth) on his assertion that these were so-called experts at that meeting. They are world-renowned experts in their field; that is just a matter of observable fact.

I want to focus on the safe use of novel mRNA agents and on concerns over their alleged role in driving excess deaths. I repeat a point that I have made previously in this place and directly with the Minister: any agent has the potential to cause harm or injury to the subject. For the avoidance of doubt, the position I have taken is based on decades of involvement in the management and delivery of clinical trials. Politicians who dismiss the data and emerging clinical evidence are acting in a wholly irresponsible manner, and posing a real threat to the duties of honesty and candour at the heart of good clinical practice. If substantiated, the concerns surfacing around falsified or concealed data are the most serious that I can imagine.

[Sir George Howarth]

The hon. Member is defending the “experts”, but has he actually checked their backgrounds? Has he checked the criticisms and the fact that, in some cases, they have had their medical practitioner status withdrawn?

[Neale Hanvey]

I am not going to get into the detail of that; I have far too little time and too many important points to make. I have worked in the same institution as Professor Dalgleish, and his credentials are impeccable.

Addressing this matter is necessary because we are talking about the standards on which good clinical practice, or GCP, is based. GCP is not about a nice bedside manner or knowing what treatment to prescribe; it is a set of internationally recognised ethical and scientific requirements, which must be followed when designing, conducting, recording and reporting on clinical trials that involve people, and have their origin in the declaration of Helsinki.

The rights, safety and wellbeing of trial subjects are the most important consideration, which should prevail over interests of science and society, including commercial or political interests, and I will conclude with a reflection on that important principle. The foundation of good clinical practice is under threat. In their December 2023 pathology research and practice paper on gene-based covid-19 vaccines, Rhodes and Parry gave the following warning:

“Pandemic management requires societal coordination, global orchestration, respect for human rights and defence of ethical principles. Yet some approaches to the COVID-19 pandemic, driven by socioeconomic, corporate, and political interests, have undermined key pillars of ethical medical science.”

None of these clinical experts are quacks or conspiracy theorists. As the Government said so often during the pandemic, we must follow the science.

[Sir Gary Streeter (in the Chair)]

Colleagues have three minutes.

--- Later in debate ---

[Maria Caulfield]

The public inquiry is independent, and the Government are under heavy scrutiny from it. It is not for me to say how the inquiry should be conducted. As a Government, we are looking at the causes of excess deaths and introducing, where we can, urgent measures to reverse that increase as quickly as possible.

No vaccine or medicine—even simple paracetamol—is completely risk free, but we have systems in place to continually monitor the safety of our medicines. For example, in April 2021, following concerns raised through the yellow card system or by GPs or clinicians, the MHRA reacted to rare cases of concurrent thrombosis and thrombocytopenia following the AZ vaccine. That resulted in actions, with adults under 30 not offered the vaccine any further. In May of that year, that was extended to adults under 40. Where there is concern, we will take action and take recommendations from bodies like the MHRA to make sure that those vaccines are as safe as they can be.

[Neale Hanvey]

The Minister knows as well as I do that the yellow card scheme sits at the heart of safe clinical care, but allegations are circulating that the MHRA is sitting on 50 times more yellow cards related to the covid-19 vaccine than those related to any other vaccine that have been reported to it. Will she commit to asking the MHRA to account for that and to taking urgent action if, indeed, it is sitting on the yellow card system reports?

[Sir Gary Streeter (in the Chair)]

Minister, please leave some time for the Member in charge to wind up.